Objectives: The aim of this study was to use serial volumetric intravascular ultrasound (IVUS) to evaluate the effects of polymer-based, paclitaxel-eluting stents on in-stent neointima formation and late incomplete stent apposition.
Background: The TAXUS-IV trial demonstrated that the slow-release, polymer-based, paclitaxel-eluting stent reduces angiographic restenosis and the need for repeat revascularization procedures. Serial IVUS studies reveal details of the pattern of vascular responses provoked by stent implantation that provide insight into device safety and efficacy.
Methods: In the TAXUS-IV trial, patients were randomized to the slow-release, polymer-based, paclitaxel-eluting TAXUS stent or a bare-metal EXPRESS stent (Boston Scientific Corp., Natick, Massachusetts). As part of a formal substudy, complete volumetric IVUS data were available in 170 patients, including 88 TAXUS patients and 82 controls, at implantation and at nine-month follow-up.
Results: No baseline differences were present in the clinical characteristics or IVUS parameters between the control and TAXUS groups. At nine-month follow-up, IVUS lumen volumes were larger in the TAXUS group (123 +/- 43 mm(3) vs. 104 +/- 44 mm(3), p = 0.005), due to a reduction in neointimal volume (18 +/- 18 mm(3) vs. 41 +/- 23 mm(3), p < 0.001). Millimeter-by-millimeter analysis within the stent demonstrated uniform suppression of neointimal growth along the entire stent length. Late lumen loss was similar at the proximal edge of the stent between the two groups, and reduced with the TAXUS stent at the distal edge (p = 0.004). Incomplete stent apposition at nine months was observed in only 3.0% of control and 4.0% of TAXUS stents (p = 0.12).
Conclusions: Polymer-based, paclitaxel-eluting TAXUS stents are effective in inhibiting neointimal tissue proliferation, and do not result in late incomplete stent apposition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2004.10.078 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Giant aneurysmal degeneration after subintimal fluoropolymer-coated paclitaxel-eluting stent implantation for the superficial femoral artery occlusion: a case report.
Eur Heart J Case Rep
December 2024
Department of Cardiology, Ishikawa Prefectural Central Hospital, 2-1, Kuratsuki-higashi Kanazawa, Ishikawa 920-8530, Japan.
Article Synopsis
- - Drug-eluting therapies, especially the Eluvia stent, have significantly reduced restenosis rates in treating peripheral artery disease, but concerns over aneurysm formation following their use are emerging.
- - An 80-year-old man developed a giant aneurysm 27 months after receiving the Eluvia stent for a blocked artery, which was identified through ultrasound and treated with endovascular-covered stents.
- - The presence of a 'low echoic area' near the stent is a common ultrasound finding after Eluvia implantation; while typically benign for two years, it can lead to serious complications like aneurysms due to factors such as overlapping stents and mechanical stress.
Polymer-based drug-eluting stent treatment extends the time to reintervention for patients with symptomatic femoropopliteal artery disease: clinical evidence and potential economic value.
J Comp Eff Res
June 2024
Institut Für Diagnostische und Interventionelle Radiologie und Neuroradiologie, Diako Hospital gGmbH, Flensburg, Germany.
Use long-term follow-up data from the IMPERIAL study to determine whether drug-eluting polymer-based nitinol stent treatment can delay the time to repeat intervention for femoropopliteal artery disease and how such a delay may result in cost savings in a value-based episode of care. The IMPERIAL randomized controlled trial was an international study of a paclitaxel-eluting polymer-coated stent (Eluvia, Boston Scientific, MA, USA) versus a polymer-free paclitaxel-coated stent (Zilver PTX, Cook Corporation, IN, USA) for treating lesions of the femoropopliteal arterial segment. Study patients (n = 465) had symptomatic lower limb ischemia.
View Article and Find Full Text PDFEfficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.
Circulation
November 2022
Ludwig-Maximilian University, Munich, Germany (K.S.).
Background: A clear patency benefit of a drug-eluting stent (DES) over bare metal stents (BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been definitively demonstrated. The EMINENT study (Trial Comparing Eluvia Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery) was designed to evaluate the patency of the Eluvia DES (Boston Scientific, Marlborough, MA), a polymer-coated paclitaxel-eluting stent, compared with BMSs for the treatment of femoropopliteal artery lesions.
Methods: EMINENT is a prospective, randomized, controlled, multicenter European study with blinded participants and outcome assessment.
Calcified nodule progression-related stent thrombosis after polymer-based paclitaxel-eluting nitinol stent implantation for femoropopliteal artery.
J Vasc Surg Cases Innov Tech
September 2021
Department of Cardiology, Tokyo Bay Medical Center, Urayasu, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!